Biotechnology
WuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022
* Revenue of RMB9,908 Million in the Second Quarter, Up 6.7% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 39.5% * Revenue of RMB18,871 Million in the First Half, Up 6.3% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 27.9% * Net Profit Attributable to Owners of the Co...
2023-07-31 18:02
4085
Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in Atopic Dermatitis (ADAMANT)
NEWARK, N.J. and NANJING, China, July 31, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced the phase 2 study initiation for the evaluation of BSI-045B, an anti-TLSP mAb, in the treatment of atopic dermatitis (AD) . "We are pleas...
2023-07-31 17:05
1533
GLOBAL SARCOMA THERAPY NOW LISTED ON PHARMACEUTICAL BENEFITS SCHEME
* YONDELIS® (trabectedin) now PBS listed for Australian patients * Listing described as "wonderful news" for patients living with rare lipo and leiomyo sarcomas * YONDELISÒ (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine1 SINGAPORE, July 31...
2023-07-31 15:00
1674
U.S. FDA Accepts Biologics License Application for GC Biopharma's GC5107B (Immune Globulin Intravenous (Human), 10% Liquid)
YONGIN, South Korea, July 31, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceutical company dedicated to specialty plasma-derived therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's resubmission of the Biologics License App...
2023-07-31 13:20
1682
Akeso Inc. Published 2023 Interim Results Positive Profit Alert
HONG KONG, July 31, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, today announced that it is expected that the Company will r...
2023-07-31 12:33
3826
NMPA and FDA Approved the First-in-Human Clinical Trial Applications to Evaluate LBL-034, An Anti-GPRC5D/CD3 Bispecific Antibody Developed by Leads Biolabs, in Relapsed/Refractory Multiple Myeloma
NANJING, China, July 31, 2023 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") announced today that the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) have approved its first-in-human Investi...
2023-07-31 12:09
1258
Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density
SUZHOU, China, July 31, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has receiv...
2023-07-31 08:10
1755
Latest Updates of 7 Viva's Portfolio Companies
HONG KONG, July 28, 2023 /PRNewswire/ -- In the face of ever-changing circumstances, technological innovation remains the eternal driving force behind the long-term growth of biopharmaceutical companies. It continuously breathes life into these enterprises, enabling them to successfully transitio...
2023-07-28 19:31
6201
HANQUYOU Marks 3rd Anniversary with Brilliant Achievements
* HANQUYOU is the China-developed biosimilar with the most marketing approvals, covering 41 countries and regions * The launch of HANQUYOU kicks off the competition between Chinese pharmaceutical companies and the world's bio-pharmaceutical companies in biosimilar monoclonal antibodies * He...
2023-07-28 15:53
3485
HANQUYOU Marks 3rd Anniversary with Brilliant Achievements
* HANQUYOU is the China-developed biosimilar with the most marketing approvals, covering 41 countries and regions * The launch of HANQUYOU kicks off the competition between Chinese pharmaceutical companies and the world's bio-pharmaceutical companies in biosimilar monoclonal antibodies * He...
2023-07-28 15:27
2756
Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Development
HONG KONG, Germantown, Md. and SUZHOU, China, July 28, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced tha...
2023-07-28 11:56
2291
Empowering Regenerative Medicine: 3A-GTP Technology Ushers in a New Epoch
Pioneering Green Energy Solutions: DrSignal Biotech and J&V Energy's Promising Alliance TAIPEI, July 27, 2023 /PRNewswire/ -- At the 2022 Healthcare Expo Taiwan, Dr.Signal Biotech showcased the remarkable 3A-GTP technology, succeeding a significant breakthrough. This technology accelerates the p...
2023-07-28 10:00
1442
Nutromics attracts world leaders in the emerging field of DNA-based sensing to join its Biosensor Advisory Board
MELBOURNE, Australia, July 28, 2023 /PRNewswire/ -- Nutromics has announced today that its lab-on-a-patch technology has attracted the support of multiple world-class experts from leading US and Australian institutions, who now comprise its Biosensor Advisory Board. Nutromics is a leader in conti...
2023-07-28 08:27
1867
2023 Tsinghua Amgen Scholars Program Kicks Off
Continuing to Empower Young Scientists SHANGHAI, July 27, 2023 /PRNewswire/ -- Recently, 2023 Amgen Scholar Program (ASP) was opened inChina, partnering with Tsinghua University, one of China's top academic institutions and influential universities. 24 undergraduates were selected as Amgen Schol...
2023-07-27 21:00
1785
HanAll Biopharma Reports Second Quarter 2023 Financial Results and Provides a Business Update
* Sales recorded KRW 41.4 billion, a 58 percent increase from the same period in 2022, due to sustained robust growth of major products in addition to milestone revenues from the progress in clinical programs of batoclimab. * Multiple clinical development milestones have been reached, includin...
2023-07-27 19:00
1958
Frost & Sullivan Awarded Duopharma Biotech with the 2022 Malaysian Company of the Year Award
Duopharma Biotech is the first pharmaceutical company to offer biosimilar products in the Malaysian market. SAN ANTONIO, July 27, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the Malaysian biosimilars industry and, based on its findings, recognizesDuopharma Biotech Berhad (Duopharma...
2023-07-27 14:00
1531
Acceptance Of Clinical Trial Application For The Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In China And Overseas Clinical Trial Progress
TAIZHOU, China, July 27, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Board") is pleased to announce that the Group has recently received the notice of acceptance (acceptance number: CXSL2300518) issued by National Medical Products Administration ("NMPA"), pursuant to which the c...
2023-07-27 10:57
4369
GC Genome enables the prognosis prediction and targeted treatment in breast cancer patients
YONGIN, South Korea, July 26, 2023 /PRNewswire/ -- GC Genome Corporation, a leading genomic diagnostics company, announced the publication of a new study in Journal of the National Cancer Institute (JNCI), shedding light on the remarkable potential of utilizing circulating tumor DNA (ctDNA) copy n...
2023-07-27 08:53
1215
Everest Medicines Announces Commercial Launch and First Prescription for XERAVA® in China
Everest transforms into a commercial-stage innovative biopharmaceutical company SHANGHAI, July 27, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicin...
2023-07-27 08:10
2138
YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023
Total revenues increase by 36.3% year-over-year; gross margin improves to 77.7%; balance sheet remains robust Company's PIKA rabies vaccine approved for Phase III clinical trials in Singapore, the Philippines, and Pakistan; interim results expected early next year GAITHERSBURG, Md., July 27, 20...
2023-07-27 05:00
4389
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8288
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7685